Terns Pharmaceuticals, Inc.
TERNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. With a market capitalization of $6.12B, it sits in mid-cap territory. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Market Cap
$6.12B
Beta
-0.38
P/E (TTM)
—
P/E (Fwd)
-36.00
EPS (TTM)
$-1.03
EPS (Fwd)
$-1.47
ROE
-14.2%
ROA
-9.9%
Cash
$1.02B
Total Debt
$919,000
Free CF
-$55.5M
52W Change
1650.4%
Annual Financials
Cash vs Debt
With $1.02B in cash and $919K in debt, TERN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$55.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -14.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Terns Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, TERN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TERN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.